Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to &lt;12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
Authors: Heeney Matthew M. , Rees David C , Allali Slimane , Odame Isaac , Cançado Rodolfo D , Inati Adlette , Cela Elena , Keefe Deborah , Reshetnyak Evgeniya , Muthusamy Velusamy Shanmuganathan , Bebrevska Lidiya , Nassin Michele L , Kanter Julie 
Published: December 2024

Introduction: SOLACE-Kids is an ongoing phase 2, open-label study to assess dosing and evaluate the safety and efficacy of crizanlizumab in pediatric patients with sickle cell disease (SCD) (ClinicalTrials.gov: NCT03474965; EudraCT: 2017-001747-12). The initial data from the 2-year analysis of 50 patients with SCD aged 12 to &lt;18 years showed that crizanlizumab 5.0 mg/kg was safe and well tolerated with clinically relevant reduction in the median annualized rate of vaso-occlusive crises (VOCs) compared with baseline (Heeney M et al. Hemasphere. 2023; S267). Here we report the first pharmacokinetic (PK), pharmacodynamic and safety data from 53 patients with SCD aged 6 to &lt;12 years who received crizanlizumab 5.0 mg/kg (n=13) or 8.5 mg/kg (n=40) after all enrolled participants had completed or discontinued treatment at least in the first 26 weeks.
Methods: Children with SCD (any genotype) and history of ≥1 VOC leading to a healthcare visit within 12 months before screening were enrolled and stratified by age: Group 1 (12 to &lt;18 years), Group 2 (6 to &lt;12 years), and Group 3 (2 to &lt;6 years). Patients received crizanlizumab with or without hydroxyurea on Day 1, Day 15, and every 4 weeks up to 2 years.
Results: As of March 02, 2023, 53 patients aged 6 to &lt;12 years received crizanlizumab 5.0 mg/kg (n=13) or 8.5 mg/kg (n=40). In the 5.0 mg/kg group, 76.9% of patients completed treatment, while in the 8.5 mg/kg group, 27.5% completed and 62.5% were still undergoing treatment. Median exposures times in the 5.0 mg/kg and 8.5 mg/kg groups were 105.9 weeks and 34.8 weeks, respectively (difference due to sequential enrolment). Dose confirmation analyses showed that crizanlizumab 5.0 mg/kg resulted in 45% and 40% lower maximum serum concentrations (Cmax) and area under the curve (AUC), respectively, from time zero to the last measurable concentration after the first infusion (AUCd15), while the 8.5 mg/kg dose achieved 52% and 40% increase in Cmax and AUCd15, respectively, confirming its use for Group 2 patients.
Mean AUCd15 and AUC after multiple doses at steady state (AUCtau) were 8180 and 14800 hr*μg/mL, respectively, in the 5.0 mg/kg group and 20600 and 35900 hr*μg/mL, respectively, in the 8.5 mg/kg group. Both groups exhibited minimal crizanlizumab accumulation, as indicated by the mean Cmax after the first infusion and at steady state (5.0 mg/kg: 65.9 and 77.5 μg/mL; 8.5 mg/kg: 175 and 171 μg/mL, respectively). Mean elimination half-life (T1/2) at steady state was 11.1 days for 5.0 mg/kg group and 12.1 days for 8.5 mg/kg group.
The arithmetic mean pre-dose P-selectin inhibition ranged from 82.3% to 98.9% for 5.0 mg/kg and 93.4% to 99.7% for 8.5 mg/kg groups, from weeks 3 to 51. The median absolute change in the annualized rate of VOCs from baseline was −0.55 in overall, −1.00 in 5.0 mg/kg and −0.53 in 8.5 mg/kg group. Five patients (38.5%) in the 5.0 mg/kg group and 11 (27.5%) in 8.5 mg/kg group were VOC free until the data cut-off.
Overall, 46 patients (86.8%) reported ≥1 adverse event (AE); 13 patients (100%) in the 5.0 mg/kg and 33 (82.5%) in 8.5 mg/kg group reported ≥1 AE. Most common AEs were pyrexia, abdominal pain and headache. Treatment-related AEs (TEAEs) occurred in 5 patients (38.5%) in 5.0 mg/kg and 12 patients (30.0%) in 8.5 mg/kg group; the most common TEAEs were infusion-related reactions (15.4% in 5.0 mg/kg and 7.5% in 8.5 mg/kg) and back pain (10% in 8.5mg/kg). Grade ≥3 AEs occurred in 6 patients (46.2%) in 5.0 mg/kg and 15 patients (37.5%) in 8.5 mg/kg group, of which anemia in 1 patient (1.9%) treated with the 8.5 mg/kg dose was reported to be related to crizanlizumab. AEs leading to dose reduction/interruption were reported in 12 patients (22.6%), of whom 4 (2 each in 5.0 and 8.5 mg/kg groups) had Grade ≥3 AEs leading to dose reduction/interruption. No AE-related treatment discontinuation or deaths were reported. Two participants (1 each in 5.0 and 8.5 mg/kg groups) developed transient antibodies against crizanlizumab, reported at the Week-27 visit. No additional antibodies against crizanlizumab were detected.
Conclusions: In this interim analysis, crizanlizumab 8.5 mg/kg dose was confirmed for patients aged 6 to &lt;12 years with SCD based on adult population PK model. Both 5.0 and 8.5 mg/kg doses showed a reduction in VOCs, resulting in decreased healthcare visits per year. Crizanlizumab was safe and well tolerated with no new/unexpected safety concerns in this patient group, consistent with the established profile of crizanlizumab in adults.